Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje,", Heroja Milana Tepića 1, Belgrade 11020, Serbia.
Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje,", Heroja Milana Tepića 1, Belgrade 11020, Serbia; Faculty of Medicine, University of Belgrade, Dr. Subotića Starijeg 8, Belgrade 11000, Serbia.
Acta Histochem. 2024 Oct;126(5-7):152183. doi: 10.1016/j.acthis.2024.152183. Epub 2024 Jul 18.
Myeloid malignancies stem from a modified hematopoietic stem cell and predominantly include acute myeloid leukemia, myelodysplastic neoplasms, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid-derived suppressor cells (MDSCs) exhibit immunoregulatory properties by governing the innate and adaptive immune systems, creating a permissive and supportive environment for neoplasm growth. This review examines the key characteristics of MDSCs in myeloid malignancies, highlighting that an increased MDSC count corresponds to heightened immunosuppressive capabilities, fostering an immune-tolerant neoplasm microenvironment. Also, this review analyzes and describes the potential of combined cancer therapies, focusing on targeting MDSC generation, expansion, and their inherent immunosuppressive activities to enhance the efficacy of current cancer immunotherapies. A comprehensive understanding of the implications of myeloid malignancies may enhance the exploration of immunotherapeutic strategies for their potential application.
髓系恶性肿瘤源自经过修饰的造血干细胞，主要包括急性髓系白血病、骨髓增生异常肿瘤、骨髓增殖性肿瘤和慢性髓单核细胞白血病。髓系来源的抑制细胞（MDSCs）通过调节先天和适应性免疫系统发挥免疫调节特性，为肿瘤生长创造一个许可和支持的环境。本综述探讨了 MDSCs 在髓系恶性肿瘤中的关键特征，强调 MDSC 计数的增加对应着更高的免疫抑制能力，促进了免疫耐受的肿瘤微环境。此外，本综述分析和描述了联合癌症治疗的潜力，重点是针对 MDSC 的产生、扩增及其固有的免疫抑制活性，以提高当前癌症免疫疗法的疗效。对髓系恶性肿瘤的影响的全面理解可以增强对免疫治疗策略的探索，以潜在地应用于这些疾病。
